Halozyme Wins Approval for Roche's Tecentriq Subcutaneous (SC) with ENHANZE in Great Britain
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the approval of Roche's Tecentriq SC, which uses Halozyme's ENHANZE drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain. The technology allows for subcutaneous delivery, reducing the delivery time from 30-60 minutes to approximately seven minutes. The drug will be available for certain types of lung, bladder, breast, and liver cancer.
August 29, 2023 | 8:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme's ENHANZE technology has been approved for use in Roche's Tecentriq SC in Great Britain. This could potentially increase the company's revenues as the drug is made available for various types of cancer.
The approval of Halozyme's ENHANZE technology for use in Roche's Tecentriq SC in Great Britain is a significant milestone for the company. This could potentially lead to increased revenues as the drug is made available for various types of cancer. The news is highly relevant to Halozyme and could have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100